Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + ofatumumab in relapsed/refractory chronic lymphocytic leukemia after fludarabine-containing therapy
2012-000634-20Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Oct 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoints: Overall response rate, Adverse events and 1 more. Started Oct 2012; status: completed.
02
Drugs
lenalidomideofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-000634-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000634-20.